Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 with POINT Biopharma
Lantheus Holdings (NASDAQ: LNTH) announced the successful closing of strategic collaboration agreements with POINT Biopharma Global, aimed at enhancing diagnostics and radiotherapeutics. The closing was subject to standard conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Act. With over 65 years of experience, Lantheus continues to focus on improving patient outcomes through innovative solutions. The agreement is expected to strengthen Lantheus' position in the life-changing radiopharmaceutical sector.
- Successful closing of collaboration agreements with POINT Biopharma, enhancing growth prospects.
- Strengthens Lantheus' position in the life-changing radiopharmaceutical market.
- None.
NORTH BILLERICA, Mass., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today announced the closing of the strategic collaboration agreements previously announced on November 14, 2022 between Lantheus and POINT Biopharma Global Inc., a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals. Closing of the agreements was subject to customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Act.
About Lantheus
With more than 65 years of experience in delivering life-changing science, Lantheus is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease. Lantheus is headquartered in Massachusetts and has offices in New Jersey, Canada and Sweden. For more information, visit www.lantheus.com.
Contacts:
Lantheus
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com
Melissa Downs
Senior Director, Corporate Communications
646-975-2533
media@lantheus.com
